Clinical trials: Advanced Rectal Cancers
Localized Advanced Rectal Adenocarcinoma
Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer
The standard treatment for locally advanced rectal cancer is neoadjuvant chemoradiotherapy followed by total mesorectal excision.
- Trial name
- NCT06931808
- Testing
- Sintilimab plus Chemotherapy, Intestinal microbiota capsules, Standard Long Course Radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Ningbo University
Colorectal Cancer
SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic or locally recurrent colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor.
- Trial name
- NCT00006001
- Testing
- semaxanib
- Where
- 10 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Rectal Cancer
64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum)
This phase II trial is assessing how 64Cu-ATSM (64Cu-copper(II) diacetylbis(N4-methylthiosemicarbazone)) PET/CT scan could predict neo adjuvant treatment response in rectum cancer locally advanced
- Trial name
- NCT03951337
- Testing
- 64Cu-ATSM
- Where
- 5 sites in France
- Volunteers
- 70 people
- Sponsor
- Institut Cancerologie de l'Ouest
Immune-related Adverse Event, Neoadjuvant Therapy
Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer
This study aims to explore the optimal number of cycles of PD-1 monotherapy required at minimum, under the premise of ensuring pathological complete response (pCR) among patients with dMMR/MSI-H rectal cancer.
- Conditions
- Immune-related Adverse Event, Neoadjuvant Therapy, dMMR Colorectal Cancer
- Trial name
- NCT06613165
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xijing Hospital
Colorectal Cancer, Esophageal Cancer
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors
This trial is an open-label, single-arm clinical study. The main purpose is to verify the safety and efficacy of CAR-T cell preparations in the treatment of CEA-positive advanced malignant tumors, and to obtain the recommended…
- Conditions
- Colorectal Cancer, Esophageal Cancer, Stomach Cancer, Pancreatic Cancer
- Trial name
- NCT05415475
- Testing
- CEA CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Metastatic Colorectal Cancer
Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer
The Primary Phase I objectives are to determine the recommended phase II dose for the capecitabine and aflibercept doublet combination; and to describe any dose limiting and non-dose limiting toxicities.
- Trial name
- X-TRAP (NCT01661972)
- Testing
- Capecitabine and aflibercept
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- John Strickler, M.D.
Colorectal Cancer, Colorectal Neoplasms
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
This is a randomized, open-label, dose/schedule optimization study comparing NUC-3373/leucovorin (LV)/irinotecan plus bevacizumab (NUFIRI-bev) to 5-FU/LV/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients…
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic
- Trial name
- NCT05678257
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan
- Where
- 59 sites in United States, France and 4 more
- Volunteers
- 180 people
- Sponsor
- NuCana plc
Cancer of Rectum
Association Between the Composition of the Intestinal Microbiota and Tumor Response in Locally Advanced Rectal Cancer
This is an observational, single-centre study (RIPH3) for patients with rectal cancer soon to be treated with chemotherapy (+/- neo-adjuvant radio-chemotherapy) looking at the relationship between the composition of the gut…
- Trial name
- Neo-Flo-Rect (NCT06181201)
- Testing
- Stool collection
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Centre Oscar Lambret
Advanced Solid Tumors
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
The purpose of this study is to evaluate the safety and tolerability of INCB099280 in combination with adagrasib and to establish the MTD or identify RDE(s) for the combination of INCB099280 and adagrasib.
- Trial name
- NCT06039384
- Testing
- INCB099280, adagrasib
- Where
- 14 sites in United States, Italy and 2 more
- Volunteers
- 6 people
- Sponsor
- Incyte Corporation
Non Small Cell Lung Cancer, Colorectal Cancer
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT05395052
- Testing
- FT536, Cyclophosphamide, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fate Therapeutics
Advanced Colorectal Cancer
A Phase II Trial of Salvage Treatment With Gemcitabine and S-1 Combination in Patients With Heavily Treated Advanced Colorectal Cancer.
To assess the efficacy and safety of salvage tratment with Gemcitabine and S-1 Combination in metastatic colorectal cancer
- Trial name
- NCT01929421
- Testing
- Gemcitabine/S-1
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Gachon University Gil Medical Center
Breast Cancer, Colorectal Cancer
Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
RATIONALE: Placing a gene into T cells may improve the body's ability to recognize cancer cells and build an immune response to fight cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT01212887
- Testing
- MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes, aldesleukin, cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Cancer Research UK
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Colorectal Cancer
SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer
To evaluate the efficacy and safety of SHR-8068 and Adebrelimab in Combination With Bevacizumabin in the treatment of microsatellite stable (MSS) advanced colorectal cancer.
- Trial name
- NCT06373133
- Testing
- SHR-8068, Adebrelimab, BP102
- Volunteers
- 36 people
- Sponsor
- West China Hospital
Colorectal Cancer, Metastatic Colorectal Cancer
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
The main purpose of this study is to test the safety, tolerable side effects, and determine the highest tolerable dose of the combination of Regorafenib and Nivolumab.
- Conditions
- Colorectal Cancer, Metastatic Colorectal Cancer, Colon Cancer
- Trial name
- NCT03712943
- Testing
- Regorafenib, Nivolumab
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Locally Advanced Rectal Cancer
Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score
This is a prospective, one arm phase II study aimed to observe the efficacy and safety of tislelizumab combined with fruquintinib in treatment of patients with pMMR / MSS locally advanced rectal cancer with high immune score.
- Trial name
- NCT04989855
- Testing
- Fruquintinib plus Tislelizumab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma
The primary purpose of this study is to evaluate the safety of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with KRAS G12D-mutated metastatic colorectal cancer (CRC) or pancreatic…
- Trial name
- NCT07859085
- Testing
- GDC-7035, Panitumumab, mFOLFOX6
- Volunteers
- 388 people
- Sponsor
- Genentech, Inc.
Advanced Cancer, Lung Cancer
Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care
In this clinical trial we want to investigate the clinical benefit of a complementary therapy using therapeutical modalities of the traditional chinese medicine in patients suffering from advanced cancer.
- Conditions
- Advanced Cancer, Lung Cancer, Breast Cancer, Colo-rectal Cancer
- Trial name
- NCT04584775
- Testing
- Treatment modalities of Traditional Chinese Medicine (Acupuncture, Chinese herbal medicine, Tunia, Chinese dietetics), Standard care
- Where
- Austria
- Sponsor
- Medical University of Graz
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.